.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,104,859

« Back to Dashboard

Details for Patent: 5,104,859

Title: Continuous administration of adenosine to reduce pulmonary vascular resistance
Abstract:This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL), and in radionucleide scintography.
Inventor(s): Sollevi; Alf (Bromma, SE)
Assignee: Solimedco Aktiebolag (Bromma, SE)
Filing Date:Dec 19, 1990
Application Number:07/630,413
Claims:1. A method for decreasing acute pulmonary vascular resistance in a human patient comprising intravenously infusion a solution of adenosine into a patient's blood stream at a rate of from bout 0.01 mg to about 0.03 mg per kg of body weight pr minute for a period sufficient to lower pulmonary vascular resistance.

2. The method according to claim 2 wherein said solution of adenosine is infused into the blood stream via a catheter introduced in a central vein.

3. The method according to claim 2 wherein said central vein is the superior vena cava.

4. The method according to claim 1 wherein said solution of adenosine is infused into the blood stream via a catheter introduced in the right atrium.

5. The method according to claim 1 wherein the concentration of adenosine in said solution is about 1.5 mg./ml. to about 6 mg./ml.

6. A method for decreasing an elevated pulmonary vascular resistance in a human patient with idiopathic respiratory distress syndrome comprising intravenously infusing about 0.010 to 0.030 mg per kg of body weight per minute of a solution of adenosine into the patient's pulmonary vasculature for a period sufficient to lower pulmonary vascular resistance.

7. The method according to claim 6 wherein said solution of adenosine is infused into the patient's pulmonary vasculature via a catheter introduced in the pulmonary artery.

8. The method according to claim 6 wherein the concentration of adenosine in said solution is about 0.1 mg./ml. to about 6 mg./ml.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc